Sino Biopharmaceutical (HKG:1177) unit Beijing Tide Pharmaceutical's TRD205 obtained breakthrough therapy designation from China's National Medical Products Administration.
The move came following positive results from a phase II clinical trial of the drug for chronic post-surgical neuropathic pain, according to a Tuesday Hong Kong bourse filing.